简单介绍

王元相,博士生导师,副教授。2017年入选中山大学“百人计划二期”。主要研究方向为药物化学:以临床重大疾病(恶性肿瘤、代谢性疾病、耐药菌等)为出发点,采取有针对性的策略,开发药效高、成药性强的药物候选物。至今已发表SCI论文24篇,他引400余次,以第一作者、或共同通讯作者发表SCI论文12篇。其中在药物化学国际一级期刊J. Med. Chem.发表论文4篇,国际著名化学综合性杂志Angew. Chem. Int. Ed发表论文1篇;作为核心发明人申请国际专利3项,国内专利3项 (已授权),其中一项已转让给国内药物开发公司。在药物化学领域积累了丰厚的经验,热忱欢迎有志于药物化学的优秀学子加入。

工作经历

2016.09-2017.07 美国亚利桑那大学药学院,药物化学,博士后

2014.10-2016.08 美国犹他大学生物化学系,生物化学,博士后

2012.08-2014.10美国亚利桑那大学药学院,药物化学,博士后

2007.09-2012.07 中国科学院上海药物研究所,药物化学,理学博士,导师:张翱 研究员

 

 

教学情况

有机化学;有机化学实验

社会/学术任职

中国药学会高级会员

 

论著专利

 

  1. Yuanxiang Wang*, Wenhao Hu, Yanqiu Yuan*. Protein Arginine Methyltransferase 5 (PRMT5) as an Anti-Cancer Target and Its Inhibitor Discovery. J. Med. Chem. 2018, 61, 9429-9441.

  2. Yuanxiang Wang, Yanmei Hu, Shuting Xu, Yongtao Zhang, Rami Musharrafieh, Raymond Kin Hau, Chunlong Ma, and Jun Wang*. In Vitro Pharmacokinetic Optimizations of AM2-S31N Channel Blockers Led to the Discovery of Slow-Binding Inhibitors with Potent Antiviral Activity against Drug-Resistant Influenza A Viruses. J. Med. Chem. 2018, 61, 1074-1085

  3. Yuanxiang Wang, Danny Hung-Chieh Chou*. A Thiol–Ene Coupling Approach to Native Peptide Stapling and Macrocyclization. Angew. Chem. Int. Ed. 2015, 54, 10931-10934.

  4. Yuanxiang Wang#, Christine E. Kaiser#, Brendan Frett, Hong-yu Li*. Targeting Mutant KRAS for Anticancer Therapeutics: A Review of Novel Small Molecule Modulators. J. Med. Chem., 2013, 56, 5219-5230.

  5. Yuanxiang Wang#, Jing Ai#, Ying Wang, Yi Chen, Lu Wang, Gang Liu, Meiyu Geng*, Ao Zhang*. Synthesis and c-Met kinase inhibition of 3,5-di- and 3,5,7-tri-substituted quinolines: Identifica- tion of 3-(4-acetylpiperazin-1-yl)-5-(3-nitroben-zylamino)-7-(trifluoromethyl) quinoline as a novel anticancer agent. J. Med. Chem201154, 2127–2142.

  6. Yuanxiang Wang, Benjamin J. Bruno, Sean Cornillie, Jason M. Nogieira, Diao Chen, Thomas E. Cheatham III, Carol S. Lim, and Danny Hung-Chieh Chou*. Application of Thiol-yne/Thiol-ene Reactions for Peptide and Protein Macrocyclizations. Chem. Eur. J. 2017, 29, 7087-7092.

  7. Yuanxiang Wang, Brendan Frett, Hong-yu Li*. Efficient Access to 2,3-Diarylimidazo[1,2‑a]pyridines via a One-Pot, Ligand-Free, Palladium-Catalyzed Three-Component Reaction underMicrowave Irradiation. Org. Lett. 201416, 3016-3019.

  8. Yuanxiang Wang, Brendan Frett, Nick McConnell, Hong-yu Li*. Metal-Free, Efficient   Hydrazination of Imidazo[1,2-a]pyridine with Diethyl Azodicarboxylate in Neutral Media. Org. Biomol. Chem. 201513, 2985-2964.

  9. Yuanxiang Wang, Biswajit Saha, Fang Li, Brendan Frett, Hong-yu Li*. An Expeditious Approach to Access 2-Arylimidazo[1,2-a]pyridin-3-ol From 2-amino pyridine Through a Novel Petasis Based Cascade Reaction. Tetrahedron Lett2014, 55, 1281-1284.

  10. Yuanxiang Wang, Jing Ai, Jinfeng Yue, Xiao Peng, Yichun Ji, Ailing Zhao, Xin Gao, Ying Wang, Yi Chen, Gang Liu, Zhaobing Gao, Meiyu Geng*, Ao Zhang*. Further SAR studies on 3,5-diamino-7-trifluoromethylquinolines as highly potent tyrosine kinase c-Met inhibitors: efforts to correct hERG inhibition. Med. Chem. Commun. 20123, 1423-1427.

  11. Yuanxiang Wang, Jing Ai, Gang Liu, Meiyu Geng, Ao Zhang. Expeditious one-pot synthesis of C3-piperazinyl-substituted quinolines: Key precursors to potent c-Met inhibitors. Org. Biomol. Chem. 20119, 5930-5933.

  12. Yuanxiang Wang, Ao Zhang. Expeditious synthesis of 2,3-dihydro-2-alkoxy-3- methylene- benzofurans from N-benzofuran-3-ylmethyl N,N,N-trialkylammonium bromides. Tetrahedron 2009, 65, 6986-6990.

  13. Diao Chen, Maria Disotuar, Xiaochun Xiong, Yuanxiang Wang, Danny Hung-Chieh Chou*. Selective N-terminal Functionalization of Native Peptides and Proteins. Chem. Sci.in press.

  14. Fang Li, Yanmei Hu, Yuanxiang Wang, Chunlong Ma, Jun Wang. Expeditious Lead Optimization of Isoxazole-Containing Influenza A Virus M2-S31N Inhibitors Using the Suzuki–Miyaura Cross-Coupling Reaction. J. Med. Chem., 2017, 60, 1580-1590.

  15. Fang Li, Chunlong Ma, Yanmei Hu, Yuanxinag Wang, Jun Wang, Discovery of potent antivirals aganist amantadine-resistant influenza A viruses by targeting the M2-S31N proton channel. ACS Infect Dis, 2016, 2, 726-733.

  16. Brendan Frett, Nick McConnell, Catherine C. Smith, Yuanxiang Wang, Neil P. Shah, Hong-yu Li. Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitors. Eur. J. Med. Chem201594, 123-131.

  17. Brendan Frett, Nick McConnell, Yuanxiang Wang, Zhigang Xu, Andrew Ambrose, Hong-yu Li. Identification of pyrazine-based TrkA inhibitors: design, synthesis, evaluation, and computational modeling studies. Med. Chem. Commun20145, 1507-1514.

  18. Brendan Frett, Yuanxiang Wang, Hong-yu Li. Targeting the K-Ras/PDEδ Protein-Protein Interaction: The Solution for Ras-Driven Cancers or Just Another Therapeutic Mirage? ChemMedChem20138, 1620-1622.

  19. Biswajit Saha, Brendan Frett, Yuanxiang Wang, Hong-yu Li. A p-toluenesulfinic acid-catalyzed three-component Ugi-type reaction and its application for the synthesis of a-amino amides and amidines. Tetrahedron Lett. 2013, 54, 2340–2343.

  20. Kui Wu, Jing Ai, Qiufeng Liu, TianTian Chen, Ailing Zhao, Xia Peng, Yuanxiang Wang, Yinchun Ji, Qizheng Yao, Yechun Xu, Meiyu Geng, Ao Zhang. Multisubstituted quinoxalines and pyrido[2,3-d]pyrimidines: Synthesis and SAR study as tyrosine kinase c-Met inhibitors. Bioorg. Med. Chem. Lett. 2012, 22, 6368-6372.